Department of Urology, Beijing Tongren Hospital Capital Medical University, Beijing, China.
BMJ Open. 2013 Dec 13;3(12):e004152. doi: 10.1136/bmjopen-2013-004152.
This study assessed the characteristics of pathogens identified in clinical isolates from patients with urinary tract infection (UTI) and their in vitro sensitivity to commonly used antibiotics in the clinical setting in China.
Multicenter study was conducted between January and December 2011 in 12 hospitals in China.
Urine samples were collected from 356 symptomatic patients treated in the study hospitals for acute uncomplicated cystitis, recurrent UTI or complicated UTI.
Minimal inhibitory concentrations (MICs) were measured using broth microdilution according to the Clinical and Laboratory Standards Institute 2011 guidelines. Thirteen antimicrobial agents were tested: fosfomycin tromethamine, levofloxacin, moxifloxacin, cefdinir, cefixime, cefaclor, cefprozil, cefuroxime, amoxicillin/clavulanic acid, cefotaxime, azithromycin, nitrofurantoin and oxacillin. Escherichia coli isolates were screened and extended spectrum β-lactamases (ESBL) production was confirmed by a double-disk synergy test.
198 urine samples were culture-positive and 175 isolates were included in the final analysis. E coli was detected in 50% of cultures, followed by Staphylococcus epidermidis (9%), Enterococcus faecalis (9%) and Klebsiella pneumoniae (5%). The detection rate of ESBL-producing E coli was 53%. Resistance to levofloxacin was the most common among all the isolates. Nitrofurantoin and fosfomycin tromethamine had the greatest activity against E coli; overall, 92% and 91% of isolates were susceptible to these antimicrobials. E faecalis had the highest susceptibility rates to fosfomycin tromethamine (100%).
The most frequently identified pathogens in our patients were ESBL-producing E coli and E faecalis. Fosfomycin tromethamine and nitrofurantoin showed a good antimicrobial activity against UTI pathogens. They may represent good options for the empiric treatment of patients with UTI.
本研究评估了中国临床尿路感染(UTI)患者临床分离病原体的特征及其对临床常用抗生素的体外敏感性。
2011 年 1 月至 12 月在中国 12 家医院进行了一项多中心研究。
研究医院治疗的 356 例急性单纯性膀胱炎、复发性 UTI 或复杂性 UTI 症状患者的尿样。
根据临床和实验室标准协会 2011 年指南,采用肉汤微量稀释法测量最小抑菌浓度(MIC)。测试了 13 种抗菌药物:磷霉素氨丁三醇、左氧氟沙星、莫西沙星、头孢地尼、头孢克肟、头孢克洛、头孢丙烯、头孢呋辛、阿莫西林/克拉维酸、头孢噻肟、阿奇霉素、呋喃妥因和苯唑西林。通过双碟协同试验筛选出大肠埃希菌分离株,并确认是否产超广谱β-内酰胺酶(ESBL)。
198 份尿样培养阳性,175 份分离物纳入最终分析。50%的培养物中检测到大肠埃希菌,其次是表皮葡萄球菌(9%)、粪肠球菌(9%)和肺炎克雷伯菌(5%)。产 ESBL 大肠埃希菌的检出率为 53%。所有分离株中对左氧氟沙星的耐药性最常见。呋喃妥因和磷霉素氨丁三醇对大肠埃希菌的活性最强;总体而言,92%和 91%的分离株对这些抗菌药物敏感。粪肠球菌对磷霉素氨丁三醇的敏感性最高(100%)。
我们患者中最常鉴定出的病原体是产 ESBL 的大肠埃希菌和粪肠球菌。磷霉素氨丁三醇和呋喃妥因对 UTI 病原体具有良好的抗菌活性。它们可能是治疗 UTI 患者的经验性治疗的良好选择。